Myriad Genetics downgraded by Wells Fargo with a new price target
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2025 | $6.00 | Sector Outperform → Sector Perform | Scotiabank |
| 5/8/2025 | Outperform → Peer Perform | Wolfe Research | |
| 5/7/2025 | $6.00 | Overweight → Equal Weight | Wells Fargo |
| 4/9/2025 | Buy → Neutral | Guggenheim | |
| 3/12/2025 | $11.50 → $12.50 | Neutral → Overweight | Piper Sandler |
| 2/12/2025 | $29.00 | Buy | Craig Hallum |
| 12/10/2024 | $18.00 | Neutral | UBS |
| 12/9/2024 | $30.00 → $21.00 | Outperform → Market Perform | Leerink Partners |
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously deliver reports to patients, while generating clinical validity and clinical utility evidence for this transformational new offering. The FirstGene screen streamlines the
SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise™ MRD Test to detect and monitor ctDNA in patients. The interim results – first shared at the 2025 ASCO Annual Meeting by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to asses
SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of genetic and tumor genomic testing solutions, coupled with its investments in research and product development, are advancing precision oncology and patient care. An oral abstract (#3007) titled "Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: